KUNMING, China, Feb. 7 /Xinhua-PRNewswire/ -- China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo," "the Company") (Amex: KUN), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People's Republic of China ("PRC"), today announced it will begin selling its 12Ways(R) Skin Care products in the United States during the first quarter of 2008.
Under a non-exclusive agreement signed with cable television and online retailer Home Shopping Group ("HSG"), China Shenghuo will launch a multi- channel marketing campaign to promote 12Ways beauty products via HSG's Web site, e-mail distribution and television commercials.
The inaugural U.S. campaign is designed to introduce five of the best- selling 12Ways products to the U.S. market, and there is potential for future sales expansion if the campaign is successful. The products will be sold as a skin care kit including moisturizer, toner, skin care mask, lotion and capsule taken to improve internal health.
"We are very pleased to partner with HSG to sell 12Ways, marking our entry into the U.S. market," said Mr. Gui Hua Lan, China Shenghuo's Chairman and Chief Executive Officer. "12Ways is a safe, natural cosmetics series derived from traditional Chinese medicine and therapy that has a long history in China. From China to the West, we believe 12Ways will be well received by the U.S. market and appeal to increasingly health-conscious consumers."
"We are excited to welcome 12Ways Skin Care into the Home Shopping Group family," said Vanessa Gomez, a senior buyer for Home Shopping Group. "These products passed through a substantial approval process, and we believe they will be well received by American consumers deciding to be more proactive about their health in the new year."
About Home Shopping Group
The Home Shopping Group is located in the Arvida Park of Commerce in Boca Raton, Florida. The Home Shopping Group uses a combination of proven marketing methods and innovative new forms of advertising to introduce products to the direct response marketplace.
About China Shenghuo Pharmaceutical Holdings, Inc.
Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo" or "the "Company") is a leading specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi- based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd. ("Kunming Shenghuo"), it owns thirty-one SFDA (State Food and Drug Association)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn
Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995: This press release contains certain "forward-looking
statements," as defined in the United States Private Securities Litigation
Reform Act of 1995, that involve a number of risks and uncertainties. There
can be no assurance that such statements will prove to be accurate and the
actual results and future events could differ materially from management's
current expectations. Such factors include, but are not limited to, the
acceptance of 12Ways products in the U.S., the company's reliance on one
supplier for Sanchi, ability to develop and market new products, ability to
establish and maintain a strong brand, continued maintenance of
certificates, permits and licenses required to conduct business in China,
protection of company's intellectual property rights, market acceptance of
the company's products, changes in the laws of the People's Republic of
China that affect the company's operations, the company's ability to obtain
all necessary government certifications and/or licenses to open and operate
retail specialty counters to offer its cosmetic products and conduct the
company's business, cost of complying with current and future governmental
regulations and the impact of any changes in the regulations on the
company's operations and other factors detailed from time to time in the
Company's filings with the United States Securities and Exchange Commission
and other regulatory authorities. The company undertakes no obligation to
publicly update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
China Shenghuo Pharmaceutical Holdings, Inc.
Ms. Gao Qionghua, CFO
CCG Elite Investor Relations
Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
|SOURCE China Shenghuo Pharmaceutical Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved